Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY DPJ Lawmakers Opposed to TPP Criticize MHLW at Hearings
October 27, 2011
-
BUSINESS GSK CEO Thinks Highly of Premiums for New Drug Creation, Key to Attractive Market
October 26, 2011
-
REGULATORY Supreme Court Upholds Ban on Reimbursement in “Mixed Healthcare”
October 26, 2011
-
BUSINESS “Sales of Teribone Can Reach ¥10 Bil.”: President Asano of Asahi Kasei Pharma
October 25, 2011
-
BUSINESS Top Drug Makers Poised to Announce 1st-Half Results: Patent Expirations Could Have Big Impact
October 25, 2011
-
BUSINESS CMIC, Medipal Set Up Joint Venture for Orphan Drugs, Develop Alliance Model
October 24, 2011
-
REGULATORY Survey Finds Slight Increase in Generic Drug Dispensing Rate
October 24, 2011
-
BUSINESS Abbott to Separate into 2 Companies
October 21, 2011
-
BUSINESS Chugai Tops Patent Asset Rankings, Teijin Jumps to Second Place
October 21, 2011
-
REGULATORY MHLW Presents Data at Chuikyo Supporting Reduction in 70% Rule for New Generics
October 20, 2011
-
COMMENTARY Impact on Japanese Pharmaceutical Companies Unavoidable: TPP Negotiations
October 19, 2011
-
BUSINESS Takeda Initiates PIII Clinical Trials for Antidiabetic TAK-875 in US, Europe
October 19, 2011
-
ORGANIZATION Keizai Doyukai’s Hasegawa Appointed National Strategy Council’s Private Sector Member, Vows “All-Out Effort
October 19, 2011
-
REGULATORY PMDA Presents Warnings on Website to Prevent Mistaken Use of 3 Taxane Drugs
October 19, 2011
-
BUSINESS MTPC Aims at Sales of ¥500 Bil. in FY2015
October 18, 2011
-
REGULATORY Council to Set Up Committee to Discuss Creation of “Drug Discovery Support Organization”
October 18, 2011
-
REGULATORY MHLW to Survey, Consider Measures for Clinical Trials in Coping with Earthquakes
October 17, 2011
-
REGULATORY Vice Minister Tsuji Supports Continuation of Premium for New Drug Development
October 17, 2011
-
BUSINESS Shionogi Completes TOB for C&O Pharmaceutical Technology of China
October 14, 2011
-
BUSINESS Doctor Survey for Information Provision Through Tablet Computers: Otsuka, Takeda Lead HP, GP
October 13, 2011
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…